Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Inhalation Anesthesia Companies

Inhalation anesthesia is a medical technique that involves administering anesthetic agents through inhalation to induce and maintain a state of controlled sedation or unconsciousness during surgical procedures. Several companies specialize in the development and manufacturing of inhalation anesthesia products, including inhalation anesthetics and related equipment.

Inhalation Anesthesia Key Companies Latest Inhalation Anesthesia Companies Update

Oct 2023: Hikma MENA FZE, a division of Hikma Pharmaceuticals, and CanariaBio have reached a distribution and licensing agreement for oregovomab, a treatment for advanced ovarian cancer. Oregovomab will be supplied throughout the Middle East and North Africa (MENA) region by Hikma MENA FZE. A murine monoclonal antibody called oregovomab targets the tumor-associated antigen CA125, which triggers a cytotoxic immune response from the host against tumor cells that display the CA 125 biomarker. Combining oregovomab with first-line chemotherapy resulted in a significantly longer progression-free survival of 41.8 months, compared to 12.2 months with standard chemotherapy, according to a randomized Phase II research. In the Phase III FLORA-5 trial, oregovomab is also being studied in patients with advanced ovarian cancer in addition to carboplatin and paclitaxel. The European Medicines Agency and the US Food and Drug Administration designated it as an orphan medicine.

The introduction of +RFID smart labels for Diprivan (Propofol) injectable emulsion, USP, 200 mg per 20 ml in single-dose vials, has been announced by Fresenius Kabi for the US market. All "major" radio-frequency identification (RFID) kits and tray systems in the nation are compatible with these smart labels. By doing away with the need for manual medication tagging, our RFID label technology improves the efficiency and safety of the medication management process while also saving time. Diprivan +RFID has been certified by Auburn University's ARC RFID laboratory and examined by The Axia Institute of Michigan State University in addition to Fresenius' testing to guarantee that it satisfies national performance and quality criteria.

List of Inhalation Anesthesia Key companies in the market

Baxter International Inc.

Halocarbon Products Corporation

Hikima Pharmaceuticals plc.

Lunan Pharmaceutical Group Co. Ltd

Piramal Enterprises Limited

Jiangsu Hengrui Medicine Co. Ltd

Fresenius Kabi AG

AbbVie Inc.

Inhalation Anesthesia Market Highlights:

Inhalation Anesthesia Market Size

Inhalation Anesthesia Market Trends

Inhalation Anesthesia Market Analysis

Inhalation Anesthesia Market Share

Inhalation Anesthesia Market Highlights:

Inhalation Anesthesia Market Trends

Inhalation Anesthesia Market Analysis

Inhalation Anesthesia Market Share

Inhalation Anesthesia Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.